세계의 Drug Discovery 서비스 시장 보고서(2025년)
Drug Discovery Services Global Market Report 2025
상품코드 : 1821628
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

Drug Discovery 서비스 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 13.8%로 343억 8,000만 달러로 성장할 것입니다. 예측 기간의 성장은 규제 프레임워크의 변화, 약물전달 시스템의 발전, 면역치료에 대한 관심 증가, RNA 기반 치료제로의 전환, 희귀질환 타겟팅 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 첨단 기술 채택, 생물학적 제제 및 바이오의약품의 성장, 하이스루풋 스크리닝 채택, 가상 스크리닝의 발전, 재생의료에 대한 관심 등이 있습니다.

향후 5년간 13.8%의 성장률 전망은 지난번 예측보다 0.5% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역장벽은 스위스나 싱가포르에서 수입되는 극저온 전자현미경 구조 분석 및 단백질 결정화 서비스 비용을 증가시키고, 신약 연구개발 비용을 상승시킴으로써 미국의 생물의학 혁신을 저해할 수 있습니다. 또한, 상호 관세와 무역 마찰 및 제한 강화로 인한 세계 경제 및 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

Drug Discovery 시험에 대한 중요성이 높아지면서 Drug Discovery 서비스 시장이 확대될 것으로 예상됩니다. 신약개발 라이프사이클은 안전하고 효과적인 약물전달을 위해 매우 중요한 역할을 담당하고 있습니다. 그 결과, 임상시험은 의약품 개발의 기본적 측면으로 그 중요성이 더욱 커지고 있습니다. 헬스케어 분야에서 의약품 개발 및 혁신의 중요성이 증가함에 따라 전 세계적으로 신약개발 임상시험에 대한 수요가 급증하고 있습니다. 예를 들어, 임상시험 등록 플랫폼인 ClinicalTrials.gov는 2023년 5월, 2021년 등록된 임상시험 수가 36만 5,000건에서 증가하여 총 45만 2,604건의 임상시험이 등록되었다고 보고했습니다. 따라서 신약개발 임상시험에 대한 관심이 높아지면서 Drug Discovery 서비스 시장의 성장을 견인할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Drug discovery services involve the process of identifying potential new medicines, utilizing a combination of scientific disciplines such as biology, chemistry, and pharmacology. These services are structured across four stage such as early drug discovery, pre-clinical phase, clinical phases, and regulatory approval.

The primary types of drug discovery services include chemistry services and biology services. Chemistry services focus on the design and synthesis of biologically active molecules, aiming to discover and optimize chemical compounds for drug development. This involves the utilization of technologies like high-performance liquid chromatography and high-field NMR for the quick and efficient synthesis, analysis, and purification of compound libraries. Key processes within chemistry services include target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation, incorporating various drug types such as biologics and small molecules. End-users of drug discovery services encompass pharmaceutical and biotechnology companies, academic institutes, and other entities involved in the drug discovery process.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The drug discovery services market research report is one of a series of new reports from The Business Research Company that provides drug discovery services market statistics, including drug discovery services industry global market size, regional shares, competitors with a drug discovery services market share, detailed drug discovery services market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery services industry. This drug discovery services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug discovery services market size has grown rapidly in recent years. It will grow from $18.27 billion in 2024 to $20.52 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increased R&D investment, expanding disease burden, government funding and support, emergence of contract research organizations (CROs), shift towards personalized medicine, drug repurposing strategies.

The drug discovery services market size is expected to see rapid growth in the next few years. It will grow to $34.38 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to regulatory framework changes, advancements in drug delivery systems, increasing interest in immunotherapy, shift towards RNA-based therapeutics, targeting rare diseases. Major trends in the forecast period include advanced technologies adoption, biologicals and biopharmaceuticals growth, adoption of high-throughput screening, advancements in virtual screening, regenerative medicine focus.

The forecast of 13.8% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade barriers could hinder U.S. biomedical innovation by increasing expenses for cryo-EM structural analysis and protein crystallization services imported from Switzerland and Singapore, elevating R&D costs for novel therapeutics. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising emphasis on drug discovery trials is anticipated to boost the drug discovery services market. The drug development life cycle plays a crucial role in ensuring the safe and effective delivery of medications. As a result, clinical trials are becoming increasingly important as a fundamental aspect of drug development. With the growing significance of drug development and innovation in healthcare, the demand for drug discovery trials has surged globally. For example, in May 2023, ClinicalTrials.gov, a platform for registering clinical trials, reported a total of 452,604 clinical trials in 2023, up from 365,000 registered trials in 2021. Therefore, the increasing focus on drug discovery trials is expected to drive the growth of the drug discovery services market.

The drug discovery services market is anticipated to witness growth driven by the rising prevalence of chronic diseases. Chronic diseases, characterized by long-lasting health conditions, necessitate ongoing management. Drug discovery services play a pivotal role in identifying and developing new medications for the treatment of chronic diseases. According to the National Library of Medicine, the US is expected to experience a 99.5% increase in the number of individuals aged 50 and older with at least one chronic condition, reaching 142.66 million by 2050. This increase in chronic diseases is poised to contribute significantly to the growth of the drug discovery services market.

Major companies in the drug discovery services market are developing advanced technologies, such as artificial intelligence (AI) and machine learning (ML), to improve the efficiency and accuracy of the drug discovery process. AI involves creating computer systems that can perform tasks typically requiring human intelligence, while ML, a subset of AI, focuses on using algorithms and statistical models to enable computers to learn from data and make predictions or decisions. For example, in February 2024, Eurofins Discovery, a France-based company providing support services across various sectors, including pharmaceuticals, announced the launch of an innovative platform called DiscoveryAI SAFIRE (Suite of ADMET Predictions for In Silico Refinement and Evaluation). This cutting-edge platform employs proprietary datasets, AI, and ML to enhance the drug discovery process. SAFIRE aims to accelerate the discovery of new pharmaceuticals by predicting the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of molecules. The platform utilizes data from Eurofins Discovery's extensive BioPrint database, meticulously curated over years of research.

Major companies within the drug discovery services market are concentrating on product innovations and developing new solutions through process visualization and centralized data management to enhance their market position. The biodrug design accelerator platform is intended to assist peptide drug discovery scientists in pharmaceutical companies by increasing the efficiency of peptide drug development, specifically through the cycles of 'design, make, test, analyze' (DMTA). For instance, in May 2023, Fujitsu, a Japan-based multinational corporation specializing in information and communications technology equipment and services, introduced the biodrug design accelerator platform to expedite peptide drug discovery research. This initiative aims to facilitate faster and more efficient drug discovery through process visualization and centralized data management. The platform helps peptide designers visualize amino acid sequences for each peptide while organizing research results systematically. It is designed to manage research processes for peptide drug discovery, which is regarded as a promising area in the field of new drug development.

In January 2023, Sygnature Discovery, a prominent UK-based integrated Drug Discovery firm, successfully concluded the acquisition of SB Drug Discovery for an undisclosed sum. This strategic move is expected to provide mutual strategic advantages, facilitating the expansion of both companies and enhancing their respective capabilities. The acquisition aligns with Sygnature's strategic plan, demonstrating a commitment to ongoing investment in the expansion of its leading integrated drug discovery solutions. SB Drug Discovery, the acquired company, is a UK-based entity specializing in providing crucial data for novel drug development through services such as cell line generation, assay development, and compound screening.

Major companies operating in the drug discovery services market are Thermo Fisher Scientific Inc., Albany Molecular Research Inc., Charles River Laboratories International Inc., Laboratory Corporation of America Holdings, Domainex Ltd., GenScript Biotech Corporation, Pharmaceutical Product Development LLC, Advinus Therapeutics Pvt. Ltd., Jubilant Biosys Ltd., Evotec AG, Syngene International Ltd., Bayer AG, Merck KGaA, Ubiquigent Ltd., Eurofins Scientific SE, AppTec Laboratory Services Inc., GVK Biosciences Private Limited, Aurigene Discovery Technologies Limited, Viva Biotech Holdings, Pharmaron Beijing Co. Ltd., Selcia Limited, Concept Life Sciences Group Limited, BioDuro LLC, ChemPartner Corporation, Aptuit LLC, Sygnature Discovery Limited, Peak Proteins Ltd., SRI International, BioAscent Discovery Limited, Sai Life Sciences Limited, Promega Corporation, MedChemExpress LLC, Aragen Bioscience Inc., WuXi STA, BioNTech SE, Moderna Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals Inc., Amgen Inc., Bristol-Myers Squibb Company

North America was the largest region in the drug discovery services market in 2024. The regions covered in the drug discovery services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug discovery services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug discovery services market includes revenues earned by entities by providing pharmaceutical services, drug metabolism and pharmacokinetics (DMPK) services, biological services, and medicinal chemistry. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Discovery Services Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drug discovery services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for drug discovery services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug discovery services market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Drug Discovery Services Market Characteristics

3. Drug Discovery Services Market Trends And Strategies

4. Drug Discovery Services Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Drug Discovery Services Growth Analysis And Strategic Analysis Framework

6. Drug Discovery Services Market Segmentation

7. Drug Discovery Services Market Regional And Country Analysis

8. Asia-Pacific Drug Discovery Services Market

9. China Drug Discovery Services Market

10. India Drug Discovery Services Market

11. Japan Drug Discovery Services Market

12. Australia Drug Discovery Services Market

13. Indonesia Drug Discovery Services Market

14. South Korea Drug Discovery Services Market

15. Western Europe Drug Discovery Services Market

16. UK Drug Discovery Services Market

17. Germany Drug Discovery Services Market

18. France Drug Discovery Services Market

19. Italy Drug Discovery Services Market

20. Spain Drug Discovery Services Market

21. Eastern Europe Drug Discovery Services Market

22. Russia Drug Discovery Services Market

23. North America Drug Discovery Services Market

24. USA Drug Discovery Services Market

25. Canada Drug Discovery Services Market

26. South America Drug Discovery Services Market

27. Brazil Drug Discovery Services Market

28. Middle East Drug Discovery Services Market

29. Africa Drug Discovery Services Market

30. Drug Discovery Services Market Competitive Landscape And Company Profiles

31. Drug Discovery Services Market Other Major And Innovative Companies

32. Global Drug Discovery Services Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drug Discovery Services Market

34. Recent Developments In The Drug Discovery Services Market

35. Drug Discovery Services Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기